27172917|t|Malignancy is associated with microcalcification and higher AP/T ratio in ultrasonography, but not with Hashimoto's thyroiditis in histopathology in patients with thyroid nodules evaluated as Bethesda Category III (AUS / FLUS) in cytology
27172917|a|The predictors of malignancy are important for the decision of appropriate management in nodules with atypia of undetermined significance / follicular lesion of undetermined significance (AUS / FLUS). Our aim was to determine the ultrasonographical, clinical, and biochemical predictors of malignancy in these patients. A total of 427 patients with cytologically Bethesda Category III (AUS / FLUS) thyroid nodules were included in this retrospective study. We divided the nodules into two subgroups according to the histopathology as benign and malignant, and compared the preoperative ultrasonographical, clinical, and biochemical findings. In overall, 427 patients with 449 AUS / FLUS nodules who had undergone surgery, the rate of malignancy was 23.4 % (105/449). When evaluated separately, the rate of malignancy was 25.8 % in nodules with AUS (82/318) and 17.6 % in nodules with FLUS (23/131) (p = 0.061). The vast majority of malignant specimens in histopathology consisted of papillary thyroid carcinoma (PTC) (n = 91, 86.7 %). Preoperative ultrasonographic features of 105 malignant nodules in histopathology were compared with the 344 benign nodules in histopathology. Anteroposterior/Transverse (AP/T) ratio was significantly higher in malignant group compared to benign group (p = 0.013). In multiple logistic analysis, we found that higher AP/T ratio and microcalcification were independently associated with malignancy (p < 0.05). The malignancy -associated cut-off value of AP/T ratio at maximum sensitivity and specificity was â‰¥0.81. We did not find any correlation between malignancy and Hashimoto's thyroiditis in histopathology in multivariate analysis (p > 0.05). In Bethesda Category III nodules with higher AP/T ratio and microcalcification, surgery might be considered as a first therapeutic option instead of repeat fine-needle aspiration biopsy or observation.
27172917	0	10	Malignancy	T038	UMLS:C4282132
27172917	30	48	microcalcification	T038	UMLS:C0521174
27172917	74	89	ultrasonography	T058	UMLS:C0041618
27172917	104	127	Hashimoto's thyroiditis	T038	UMLS:C0677607
27172917	131	145	histopathology	T058	UMLS:C0430445
27172917	163	178	thyroid nodules	T038	UMLS:C0040137
27172917	192	213	Bethesda Category III	T038	UMLS:C0040137
27172917	215	218	AUS	T038	UMLS:C0522580
27172917	221	225	FLUS	T033	UMLS:C1272585
27172917	230	238	cytology	T058	UMLS:C1305671
27172917	243	253	predictors	T170	UMLS:C0683956
27172917	257	267	malignancy	T038	UMLS:C4282132
27172917	314	324	management	T058	UMLS:C0376636
27172917	328	335	nodules	T038	UMLS:C0040137
27172917	341	376	atypia of undetermined significance	T038	UMLS:C0522580
27172917	379	425	follicular lesion of undetermined significance	T033	UMLS:C1272585
27172917	427	430	AUS	T038	UMLS:C0522580
27172917	433	437	FLUS	T033	UMLS:C1272585
27172917	469	487	ultrasonographical	T170	UMLS:C0683956
27172917	489	497	clinical	T170	UMLS:C0683956
27172917	503	525	biochemical predictors	T170	UMLS:C0683956
27172917	529	539	malignancy	T038	UMLS:C4282132
27172917	588	623	cytologically Bethesda Category III	T038	UMLS:C0040137
27172917	625	628	AUS	T038	UMLS:C0522580
27172917	631	635	FLUS	T033	UMLS:C1272585
27172917	637	652	thyroid nodules	T038	UMLS:C0040137
27172917	675	694	retrospective study	T062	UMLS:C0035363
27172917	711	718	nodules	T038	UMLS:C0040137
27172917	728	737	subgroups	T098	UMLS:C1257890
27172917	755	769	histopathology	T058	UMLS:C0430445
27172917	825	843	ultrasonographical	T201	UMLS:C1720195
27172917	845	853	clinical	T201	UMLS:C3854293
27172917	859	879	biochemical findings	T033	UMLS:C0243095
27172917	915	918	AUS	T038	UMLS:C0522580
27172917	921	925	FLUS	T033	UMLS:C1272585
27172917	926	933	nodules	T038	UMLS:C0040137
27172917	952	959	surgery	T058	UMLS:C0543467
27172917	973	983	malignancy	T038	UMLS:C4282132
27172917	1045	1055	malignancy	T038	UMLS:C4282132
27172917	1070	1077	nodules	T038	UMLS:C0040137
27172917	1083	1086	AUS	T038	UMLS:C0522580
27172917	1110	1117	nodules	T038	UMLS:C0040137
27172917	1123	1127	FLUS	T033	UMLS:C1272585
27172917	1194	1208	histopathology	T058	UMLS:C0430445
27172917	1222	1249	papillary thyroid carcinoma	T038	UMLS:C0238463
27172917	1251	1254	PTC	T038	UMLS:C0238463
27172917	1287	1312	ultrasonographic features	T201	UMLS:C1720195
27172917	1320	1337	malignant nodules	T038	UMLS:C0040137
27172917	1341	1355	histopathology	T058	UMLS:C0430445
27172917	1383	1397	benign nodules	T038	UMLS:C0749467
27172917	1401	1415	histopathology	T058	UMLS:C0430445
27172917	1485	1500	malignant group	T098	UMLS:C1257890
27172917	1513	1525	benign group	T098	UMLS:C1257890
27172917	1542	1568	multiple logistic analysis	T062	UMLS:C0936012
27172917	1606	1624	microcalcification	T038	UMLS:C0521174
27172917	1660	1670	malignancy	T038	UMLS:C4282132
27172917	1687	1697	malignancy	T038	UMLS:C4282132
27172917	1828	1838	malignancy	T038	UMLS:C4282132
27172917	1843	1866	Hashimoto's thyroiditis	T038	UMLS:C0677607
27172917	1870	1884	histopathology	T058	UMLS:C0430445
27172917	1925	1954	Bethesda Category III nodules	T038	UMLS:C0040137
27172917	1982	2000	microcalcification	T038	UMLS:C0521174
27172917	2002	2009	surgery	T058	UMLS:C0543467
27172917	2078	2107	fine-needle aspiration biopsy	T058	UMLS:C1510483
27172917	2111	2122	observation	T062	UMLS:C0302523